Ashis Roy (TCGLS Member), Dr. Mrinalkanti Kundu (TCGLS Member), Dr. Pranab Dhar (TCGLS Member), Arnish Chakraborty (TCGLS Member), Dr. Soumen Mukherjee (TCGLS Member), Jayatri Naskar (TCGLS Member), Dr. Chhanda Rarhi (TCGLS Member), Dr. Rajib Barik (TCGLS Member), Dr. Susanta Kumar Mondal (TCGLS Member), Mushtaq Ahmad Wani, Rahul Gajbhiye, Prof. Kuldeep K. Roy, Dr. Arup Maiti (TCGLS Member), Priyadarshi Manna (TCGLS Member), Prof. Susanta Adhikari
DOI : https://doi.org/10.1002/slct.202000208
Abstract
A series of novel bicyclic, substituted pyrimidinone compounds were designed, synthesized, and characterized. In vitro anti‐proliferative activity of the synthesized compounds was evaluated against six different human cancer cell lines using MTT assay. Among all twenty-four compounds tested, compound 22 (N‐([1,1′‐biphenyl]‐4‐yl)‐2‐((3‐methyl‐4‐oxo‐6,7,8,9‐tetrahydro‐4Hpyrido[1,2‐a]pyrimidin‐2‐yl)oxy)acetamide) exhibited significant cell growth inhibition of human liver cancer cells HepG2 with GIC50 (50% growth inhibitory concentration) value of 120+10 nM and was found to be selective over healthy human embryonic kidney (HEK) cell line (33.1% inhibition at 20 μM). Further studies demonstrated that compound 22 induced cell apoptosis in HepG2 cells and resulted in a similar effect to Staurosporine, a well known proapoptotic compound widely used to induce apoptosis in various cancer cell lines. Compound 22 also rendered acceptable aqueous solubility (3.5+0.37 μM, at pH 7.4) and attractive metabolic stability against human liver microsomes with a half‐life of 34.63+0.33 minutes. Based on the similarity observed between the known tankyrase‐1 inhibitors available in the literature and compound 22, in silico docking study was performed and the results suggested that the compound interacted with the key amino acid residues present in the tankyrase‐1 enzyme active site.
Published in: Journal Volume : 502, Pages : 119286
DOI : 10.1016/j.ica.2019.119286
Author : Asthana, Mrityunjaya; Syiemlieh, Ibanphylla; Kumar, Arvind; Lal, Ram A.
Abstract : A ligand and additive-free [CuNi(bz)3(bpy)2]ClO4 catalyst system that efficiently and selectively catalyzed the oxidation of a range of primary and secondary benzylic alcs., 1-heteroaryl alcs., cinnamyl alc. and aliphatic alcs. mediated by hydrogen peroxide to the corresponding aldehydes and ketones, resp.
Published in: Journal, General Review, Article, Review Volume : 5, Issue : 6, Pages : 2503-2519
DOI : 10.1021/acsomega.9b03686
Author : Mahato, Sanjit K.; Acharya, Chiranjit; Wellington, Kevin W.; Bhattacharjee, Pinaki; Jaisankar, Parasuraman
Abstract : A review. This review deals with the recent applications of the indium trichloride (InCl3) catalyst in the synthesis of a broad spectrum of heterocyclic compounds Over the years, a number of reviews on the applications of InCl3-catalyzed organic synthesis have appeared in the literature. It is evident that InCl3 has emerged as a valuable catalyst for a wide range of organic transformations due to its stability when exposed to moisture and also in an aqueous medium. The most attractive feature of this review is the application of the InCl3 catalyst for synthesizing bioactive heterocyclic compounds The study of InCl3-catalyzed organic reactions has high potential and better intriguing aspects, which are anticipated to originate from this field of research.
Trisha Mitra (TCGLS Member), Brindaban Roy and Mrinalkanti Kundu (TCGLS Member)
The Journal of organic chemistryJournal; Article; (JOURNAL ARTICLE), 2019
DOI: 10.1021/acs.joc.9b02122
Small molecules containing a 2-pyridone unit received much attention due to their significance in medicinal chemistry. In this regard, development of novel methodologies via metal-catalyzed carbon-carbon bond formation by chelation-assisted C-H activation will be an attractive method to achieve therapeutically important 2-pyridone analogues and arylated acid synthons. We report our studies on a Pd(II)-catalyzed coupling reaction between methyl, aryl, heteroaryl iodides, and sp(2) carbons both at β- and γ-positions using 3-amino-1-methyl-1H-pyridin-2-one as an efficient, built-in bidentate N,O-directing group (DG) toward the synthesis of pyridone derivatives. The effect of temperature, solvent, reagent equivalence, and substrate has been investigated for this DG-mediated late-stage functionalization reactions along with the crystal structure of a selected analogue. Moreover, this DG has been successfully applied for ortho-selective C(sp(2))-H activation in aqueous medium in high yields to demonstrate the practicability of this present methodology.
Bhawana Gupta (TCGLS Member), Sabyasachi Chakraborty (TCGLS Member), Soumya Saha (TCGLS Member), Sunita Chandel (TCGLS Member), Gulab Singh (TCGLS Member), Atul Kumar Baranwal (TCGLS Member), Manish Banerjee (TCGLS Member), Mousumi Chatterjee (TCGLS Member), Ashok Chaudhury.
Canadian Journal of Physiology and Pharmacology Volume 94 Issue 7 Pages 788-796, 1996
DOI: 10.1139/cjpp-2015-0465
Shikonin possess a diverse spectrum of Pharmacol. properties in multiple therapeutic areas. However, the nociceptive effect of shikonin is not largely known. To investigate the antinociceptive potential of shikonin, panel of GPCRs, ion channels, and enzymes involved in pain pathogenesis were studied. To evaluate the translation of shikonin efficacy in vivo, it was tested in 3 established rat pain models. Our study reveals that shikonin has significant inhibitory effect on pan sodium channel/N1E115 and NaV1.7 channel with half maximal inhibitory concn. (IC50) value of 7.6 μmol/L and 6.4 μmol/L, resp., in a cell-based assay. Shikonin exerted significant dose dependent antinociceptive activity at doses of 0.08%, 0.05%, and 0.02% w/v in pinch pain model. In mech. hyperalgesia model, dose of 10 and 3 mg/kg (i.p.) produced dose-dependent analgesia and showed 67% and 35% reversal of hyperalgesia resp. at 0.5 h. Following oral administration, it showed 39% reversal at 30 mg/kg dose. When tested in first phase of formalin induced pain, shikonin at 10 mg/kg dose inhibited paw flinching by ∼71%. In all studied preclin. models, analgesic effect was similar or better than std. analgesic drugs. The present study unveils the mechanistic role of shikonin on pain modulation, predominantly via sodium channel modulation, suggesting that shikonin could be developed as a potential pain blocker
Rajesh Malhotra, Chhanda Rarhi (TCGLS Member), K V Diveshkumar, Ruhee D’cunha, Rajib Barik( TCGLS Member), Pranab Dhar (TCGLS Member), Subrata Chattopadhyay (TCGLS Member), Subho Roy (TCGLS Member), Sourav Basu, Mrinalkanti Kundu (TCGLS Member), P I Pradeepkumar, Saumen Hajra
Bioorganic & Medicinal Chemistry Volume 24, Issue 13, 1 July 2016, Pages 2887–2896
DOI: 10.1016/j.bmc.2016.04.059
A convenient route was envisaged toward the synthesis of dihydrochelerythrine (DHCHL), 4 by intramolecular Suzuki coupling of 2-bromo-N-(2-bromobenzyl)-naphthalen-1-amine derivative 5 via in situ generated arylborane. This compound was converted to (±)-6-acetonyldihydrochelerythrine (ADC), 3 which was then resolved by chiral prep-HPLC. The efficiency of DHCHL for the stabilization of promoter quadruplex DNA structures and a comparison study with the parent natural alkaloid chelerythrine (CHL), 1 was performed. A thorough investigation was carried out to assess the quadruplex binding affinity by using various biophysical and biochemical studies and the binding mode was explained by using molecular modeling and dynamics studies. Results clearly indicate that DHCHL is a strong G-quadruplex stabilizer with an affinity similar to that.
at of the parent alkaloid CHL. Compounds ADC and DHCHL were also screened against different human cancer cell lines. Among the cancer cells, (±)-ADC and its enantiomers showed varied (15-48%) inhibition against human colorectal cell line HCT116 and breast cancer cell line MDA-MB-231 albeit low enantio-specificity in the inhibitory effect; whereas DHCHL showed 30% inhibition against A431 cell line only, suggesting the compounds are indeed cancer tissue-specific.
Tathagata Sengupta(TCGLS Member), Rishi Das (TCGLS Member), Sumantra Chattarji
Neuroscience Letters (2016), 633, 101-105.
DOI: 10.1016/j.neulet.2016.09.031
Abstract: Acute stress has been shown to facilitate but not increase metabotropic glutamate receptor (mGluR) mediated Long-Term Depression (LTD) in the hippocampus. However, the effect of chronic stress on mGluR dependent LTD has not been investigated. Moreover, whether stress leads to a transient modification LTD threshold or a more stable change in synaptic plasticity needs to be addressed. In the present study, we have explored the effects of both a ten-day long and a single day immobilization stress protocol on mGluR-LTD at the CA3:CA1synapse in the hippocampus of adult male Sprague-Dawley rats, a day after applying stress. Bath application of the selective group 1 mGluR agonist (S)-3,5-dihydroxyphenylglycine (DHPG) promoted robust LTD in hippocampal slices from control (i.e. un-stressed) animals. Administration of immobility stress for two hours per day for ten days significantly elevated this LTD to a level almost twice that of control, when observed 24h following the last stress event. Acute stress i.e. a single day of two hours of immobilization, however, failed to significantly enhance LTD, 24h later. These results demonstrate for the first time, that repeated exposure to stress, but not a single stress event, is required to bring about a stable alteration in mGluR mediated synaptic plasticity.
Igawa Hideyuki; Takahashi Masashi; Shirasaki Mikio; Kakegawa Keiko; Kina Asato; Ikoma Minoru; Aida Jumpei; Okuda Shoki; Kawata Yayoi; Noguchi Toshihiro; Yamamoto Syunsuke; Fujioka Yasushi; Nakayama Masaharu; Kasai Shizuo; Maekawa Tsuyoshi; Yasuma Tsuneo; Kundu Mrinalkanti; Khamrai Uttam (TCGLS Member); Nagisa Yasutaka
Bioorganic & Medicinal Chemistry Volume 24, Issue 11, 1 June 2016, Pages 2486–2503
DOI : 10.1016/j.bmc.2016.04.011
Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally featured an imidazo[1,2-a]pyridine-based bicyclic motif. To investigate imidazopyridine variants with lower basicity and less potential to inhibit cytochrome P450 3A4 (CYP3A4), we designed pyridine-2(1H)-ones bearing various less basic bicyclic motifs. Among these, a lead compound 6a bearing a 1H-benzimidazole motif showed comparable binding affinity to MCHR1 to the corresponding imidazopyridine derivative 1. Optimization of 6a afforded a series of potent thiophene derivatives (6q-u); however, most of these were found to cause time-dependent inhibition (TDI) of CYP3A4. As bioactivation of thiophenes to form sulfoxide or epoxide species was considered to be a major cause of CYP3A4 TDI, we introduced electron withdrawing groups on the thiophene and found that a CF3 group on the ring or a Cl adjacent to the sulfur atom helped prevent CYP3A4 TDI. Consequently, 4-[(5-chlorothiophen-2-yl)methoxy]-1-(2-cyclopropyl-1-methyl-1H-benzimidazol-6-yl)pyridin-2(1H)-one (6s) was identified as a potent MCHR1 antagonist without the risk of CYP3A4 TDI, which exhibited a promising safety profile including low CYP3A4 inhibition and exerted significant antiobesity effects in diet-induced obese F344 rats.
Mahato, Chandan K. (TCGLS Member); Kundu, Mrinalkanti (TCGLS Member); Pramanik, Animesh (TCGLS Member)
Tetrahedron: Asymmetry 2017, 28(4), 511-515
DOI : https://doi.org/10.1016/j.tetasy.2017.03.002
Abstract: New chiral organocatalysts are envisaged based on a pyrrolidine–pyridone conjugate and synthesized from commercially available proline employing standard protocols. These catalysts were found to be useful for asymmetric Michael additions of ketones to nitroolefins to afford the desired products in very good yields (up to 98%) with excellent diastereo- and enantioselectivities (>97:3 syn/anti and up to 98% ee) in very short reaction time compared with the existing reports
Schwertz Geoffrey; Siggel Marc; Zwyssig Adrian; Diederich Francois; Witschel Matthias C; Aponte Raphael A; Rottmann Matthias; Schafer Anja; Rottmann Matthias; Schafer Anja; Bonnert Roger; Leartsakulpanich Ubolsree; Chitnumsub Penchit; Jaruwat Aritsara; Ittarat Wanwipa; Charman Susan A; White Karen L; Kundu Abhijit (TCGLS Member); Sadhukhan Surajit (TCGLS Member); Lloyd Mel; Freiberg Gail M; Srikumaran Myron; Chaiyen Pimchai
DOI: https://doi.org/10.1021/acs.jmedchem.7b00008
Journal of Medicinal Chemistry 2017, 60(12), 4840-4860
Abstract: Target-based approaches toward new antimalarial treatments are highly valuable to prevent resistance development. We report several series of pyrazolopyran-based inhibitors targeting the enzyme serine hydroxymethyltransferase (SHMT), designed to improve microsomal metabolic stability and to identify suitable candidates for in vivo efficacy evaluation. The best ligands inhibited Plasmodium falciparum (Pf) and Arabidopsis thaliana (At) SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range (3.2-55 nM). A set of carboxylate derivatives demonstrated markedly improved in vitro metabolic stability (t1/2 > 2 h). A selected ligand showed significant in vivo efficacy with 73% of parasitemia reduction in a mouse model. Five new cocrystal structures with PvSHMT were solved at 2.3-2.6 ÅA resolution, revealing a unique water-mediated interaction with Tyr63 at the end of the para-aminobenzoate channel. They also displayed the high degree of conformational flexibility of the Cys364-loop lining this channel
.jpg ?>)
.jpg ?>)
